Summit Therapeutics SMMT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -271%-147pp | -206.1%-111pp | -292.5%-219pp | -328.3%-226pp | -123.9%+6.7pp | |
| Liquidity | ||||||
| Current ratio | 7.4×-3.2× | 9.9×-0.3× | 3.8×-4.5× | 5.1×+2.8× | 10.6×+3.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×-2.5× | |
| Per Share | ||||||
| Book value per share | $0.70+50.9% | $0.88+62.9% | $0.26-57.1% | $0.35+26.8% | $0.47+640% | |
| Valuation | ||||||
| Market capitalization | $14.7B+3.3% | $13.02B-1.1% | $15.35B-0.2% | $15.54B+180% | $14.23B+390% | |
| Price / book | 26.9×-14.4× | 19.8×-14.1× | 79.8×+44.7× | 59.9×+31.5× | 41.3×-24.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Summit Therapeutics's ratios come from?
- Every ratio is computed from Summit Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.